However, recently published studies with SEC, another IL17A inhibitor, show that neither obesity nor any other element of the metabolic syndrome (MetS) appears to negatively influence survival of this therapeutic class [8,9]. Here, IL17A is linked to obesity due to melanocortin 4 receptor deficiency.